REVIEW
Accepted on 24 Dec 2025
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Checkpoint immunotherapy: Reshaping the landscape of gastrointestinal cancer treatment - Volume II
Checkpoint immunotherapy: Reshaping the landscape of gastrointestinal cancer treatment - Volume II
1,074
Total downloads
12k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Accepted on 19 Dec 2025
Neoadjuvant Serplulimab and SOX Chemotherapy for Locally Advanced Gastric Cancer: Pathological Responses and Systemic Immune Signatures from a Phase II Trial
- 141 views
MINI REVIEW
Published on 17 Dec 2025
Perioperative immunotherapy in gastric cancer: walking a fine line between hope and caution
doi 10.3389/fimmu.2025.1722749
- 651 views
STUDY PROTOCOL
Accepted on 16 Dec 2025
XELOX Combined With Sintilimab and Hyperbaric Oxygen Therapy for Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Study Protocol for a Prospective, Single-Arm, Phase Ib/II Clinical Trial
- 155 views
ORIGINAL RESEARCH
Published on 09 Dec 2025
Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China
doi 10.3389/fimmu.2025.1676293
- 878 views
ORIGINAL RESEARCH
Published on 31 Oct 2025
Targeting Pin1 to overcome immunosuppressive tumor microenvironment in MSS colorectal cancer
doi 10.3389/fimmu.2025.1677029
- 2,471 views
ORIGINAL RESEARCH
Published on 22 Oct 2025
Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort
doi 10.3389/fimmu.2025.1700400
- 1,329 views
SYSTEMATIC REVIEW
Published on 15 Oct 2025
First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials
doi 10.3389/fimmu.2025.1667793
- 2,167 views
- 1 citation
CASE REPORT
Published on 30 Sep 2025
Efficacy of cadonilimab in combination with nimotuzumab and AG regimen in TMB-H/KRAS wild-type advanced pancreatic cancer: a case report
doi 10.3389/fimmu.2025.1652827
- 1,269 views
ORIGINAL RESEARCH
Published on 13 Aug 2025
Preexisting ulcerative colitis increases the risk of immune-related colitis and predicts divergent survival outcomes in gastrointestinal cancer patients treated with immune checkpoint inhibitors
doi 10.3389/fimmu.2025.1627680
- 1,633 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Other participating journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: